Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart in Multifocal Motor Neuropathy
NCT07610564Phase 1Recruiting
- Sponsor
- argenx
- Start
- Jul 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of empasiprubart in multifocal motor neuropathy (MMN), sponsored by argenx. Primary endpoint: Cross-Sectional Area of Nerve at 48 weeks. Started Jul 2026; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT07610564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610564.